The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mikheeva O.O.

M.M. Shemyakin — Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow, Russia

Domogatsky S.P.

Institute of Experimental Cardiology of the National Medical Research Center of Cardiology, Moscow, Russia

Efremov E.E.

Institute of Experimental Cardiology of National Medical Research Center of Cardiology, Moscow, Russia

Esipov R.S.

M.M. Shemyakin — Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow, Russia

Molecular markers for diagnostics of cardiac failure

Authors:

Mikheeva O.O., Domogatsky S.P., Efremov E.E., Esipov R.S.

More about the authors

Journal: Russian Cardiology Bulletin. 2018;13(4): 62‑67

DOI: 10.17116/Cardiobulletin20181304162

Read: 5135 times

Download PDF (RU)
Contact the author
Table of contents

MOLECULAR MARKERS FOR DIAGNOSTICS OF CARDIAC FAILURE
MOLECULAR MARKERS FOR DIAGNOSTICS OF CARDIAC FAILURE

To cite this article:

Mikheeva OO, Domogatsky SP, Efremov EE, Esipov RS. Molecular markers for diagnostics of cardiac failure. Russian Cardiology Bulletin. 2018;13(4):62‑67. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20181304162

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Comparative analysis of methods for diagnosing sleep apnea. Russian Rhinology. 2025;(2):137-142
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Sacral dysmorphism in patients with traumatology and orthopedics. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2):30-37
Transapical myectomy in a child with hype­rtrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):357-362
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Abstract:

Modern approaches to diagnose cardiac failure are based on instrumental methods capable to evaluate a patient’s condition. The most informative mean for stratification of cardiovascular mortality risks or probability of repeated hospitalization is the comprehensive analysis of measured concentrations of the specific molecular markers — peptides or proteins, associated with the disease progress. The review contains a list of their parameters and the data on the evaluation of the clinical significance of determination of the major markers levels that are uses for cardiac failure diagnostics. It is noted that not a single one of the mentioned markers possesses a sufficient degree of correlation with the manifestation of clinical symptoms, whereas the best prediction can be received during a combined use of these biomarkers.

Keywords:

cardiac failure
diagnostics
prognosis
biomarkers
multiparameter approach

Authors:

Mikheeva O.O.

M.M. Shemyakin — Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow, Russia

Domogatsky S.P.

Institute of Experimental Cardiology of the National Medical Research Center of Cardiology, Moscow, Russia

Efremov E.E.

Institute of Experimental Cardiology of National Medical Research Center of Cardiology, Moscow, Russia

Esipov R.S.

M.M. Shemyakin — Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of RAS, Moscow, Russia

Close metadata

References:

  1. Edit Tanai, and Stefan Frantz. Pathophysiology of Heart Failure. Comprehensive Physiology. 2016;6.
  2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146. https://doi.org/10.1136/hrt.2003.025270
  3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. 1979;JAMA241:2035-2038.
  4. Bers DM. Altered cardiac myocyte Ca regulation in heart failure. Physiology. 2006;21:380-387. https://doi.org/10.1152/physiol.00019.2006
  5. Van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: A balancing act. Cardiovasc Res. 2004;63:487-499. https://doi.org/10.1016/j.cardiores.2004.02.013
  6. Van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67:21-29. https://doi.org/10.1016/j.cardiores.2005.04.012
  7. Protasov VN, Skvortsov AA, Koshkina DE, Narusov OYu, Tereshchenko SN. Use of new biomarkers in risk stratificationof patients with heart failure. Kardiologicheskij vestnik. 2014;4:100-107. (In Russ.)
  8. Koshkina DE, Skvortsov AA, Protasov VN, Narusov OYu, Tereshchenko SN. The Role of Markers of Organ Damage in Patients With Chronic Heart Failure. Kardiologiya. 2015;55:(1):70-76. (In Russ.) https://doi.org/10.18565/cardio.2015.1.70-76
  9. Protasov VN, Skvortsov AA, Narusov OYu, Koshkina DE, Tkachev GA, Goryunova TV, Masenko VP, Tereshchenko SN. Supression of tumorogenicity 2 significance in patients with heart failure decompensation. Heart Failure. 2017;18:(4):279-289. (In Russ.) https://doi.org/10.18087/RHFJ.2017.4.2370
  10. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10:1111-1114. https://doi.org/10.1097/00004872-199210000-00002
  11. Jortani SA, Prabhu SD, Valdes R, Jr. Strategies for developing biomarkers of HF. Clin Chem. 2004;50:265-278. https://doi.org/10.1373/clinchem.2003.027557
  12. Saremi A, Gopal D, Maisel AS. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated HF. Expert Rev Cardiovasc Ther. 2012;10:191-203. https://doi.org/10.1586/erc.11.188
  13. Xu-Cai YO, Wu Q. Molecular forms of natriuretic peptides in HF and their implications. Heart. 2009;96:6:419-424. https://doi.org/10.1136/hrt.2008.164145
  14. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003;4:72-80.
  15. Semenov AG, Tamm NN, Seferian KR, et al. Processing of Pro-B-Type Natriuretic Peptide Furin and Corin as Candidate Convertases. Clin Chem. 2010;56:1166-1176. https://doi.org/10.1373/clinchem.2010.143883
  16. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of HF. Heart. 2005;91:606-612. https://doi.org/10.1136/hrt.2004.037762
  17. Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic HF: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53:1783-1790. https://doi.org/10.1016/j.jacc.2009.01.057
  18. Jougasaki M, Grantham JA, Redfield MM, et al. Regulation of cardiac adrenomedullin in HF. Peptides. 2001;22:1841-1850. https://doi.org/10.1016/s0196-9781(01)00527-7
  19. Meeran K, O’Shea D, Upton PD, et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab. 1997;82:1:95-100. https://doi.org/10.1210/jc.82.1.95
  20. Muhammad Tarmizi Soleh, Jared Yong Yang Foo. A rapid and cost-effective method of producing recombinant proBNP and NT-proBNP variants in Escherichia coli for immunoassay of heart failure. Biotechnology Letters. 2014;36:1:133-140. https://doi.org/10.1007/s10529-013-1341-0
  21. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:6159:78-81. https://doi.org/10.1038/332078a0
  22. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, Shirakami G, Jougasaki M, Imura H. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757-758. https://doi.org/10.1172/jci115146
  23. Cowie MR, Jourdain P, Maisel AS, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710-1718. https://doi.org/10.1016/s0195-668x(03)00476-7
  24. Maisel A, Muller C, Adams K Jr, et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-839. https://doi.org/10.1016/j.ejheart.2008.07.014
  25. Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Study. Am Heart J. 2006;151:999-1005. https://doi.org/10.1016/j.ahj.2005.10.011
  26. Van der Burg-de Graauw N, Cobbaert CM, Middelhoff CJ, et al. The additive value of N-terminal pro-B-type natriuretic peptide testing at the ED in patients with acute dyspnea. Eur J Intern Med. 2009;20:301-306. https://doi.org/10.1016/j.ejim.2008.09.022
  27. Skvortsov AA, Koshkina DE, Narusov OYu, Protasov VN, Masenko VP, Tereshchenko SN. Therapy of high risk patients after decompensation of heart failure under NT-proBNP Control. Main Results. Kardiologiya. 2016;56:7:25-38. (In Russ.) https://doi.org/10.18565/cardio.2016.7.25-38
  28. Waldo SW, Beede J, Isakson S, et al. Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure. J Am Coll Cardiol. 2008;51:1874-1882. https://doi.org/10.1016/j.jacc.2007.12.051
  29. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (BiomarÂkers in Acute HF) trial. J Am Coll Cardiol. 2010;55:2062-2076. https://doi.org/10.1016/j.jacc.2010.02.025
  30. Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident HF and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712-1719. https://doi.org/10.1016/j.jacc.2010.05.049
  31. Von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic HF. J Am Coll Cardiol. 2007;50:1973-1980. https://doi.org/10.1016/j.jacc.2007.08.012
  32. Klip IT, Voors AA, Anker SD, et al. Prognostic value of mid-regional pro-adrenomedullin in patients with HF after an acute myocardial infarction. Heart. 2011;97:892-898. https://doi.org/10.1136/hrt.2010.210948
  33. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549. https://doi.org/10.1172/jci30634
  34. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocites and myocardial infarction. Circulation. 2002;106:2961-2966. https://doi.org/10.1161/01.cir.0000038705.69871.d9
  35. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea. J Am Coll Cardiol. 2007;50:607-613. https://doi.org/10.1016/j.jacc.2007.05.014
  36. Josep Maria Aran Perramon. Genetically modified mesenchymal stem cells expressing sST2 for the treatment of airway immune inflammatory and lung disease. US patent 9339518B2. November 24, 2011. https://patents.google.com/patent/us9339518/un
  37. Ago T, Sadoshima J. GDF-15, a cardioprotective TGF-B superfamily protein. AHA Journals. 2011. https://doi.org/10.1161/01.res.0000207919.83894.9d
  38. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol. 2000;20:3742-3751. https://doi.org/10.1128/mcb.20.10.3742-3751.2000
  39. Wang F, Guo Y, Yu H, et al. Growth differentiation factor 15 in different stages of HF: potential screening implications. Biomarkers. 2010;15:671-676. https://doi.org/10.3109/1354750x.2010.510580
  40. Dinh W, Futh R, Lankisch M, et al. Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction? Sociedade Brasileira de Cardologia. 2011. https://doi.org/10.1590/s0066-782x2011005000058
  41. Unsicker K, Kriegelstein K. Neuroprotective properties of GDF-15, a novel member of the TGF-β superfamily. Patent WO2000070051A1. 2000-11-23.
  42. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with HF. Rev Cardiovasc Med. 2011;12:200-210. https://doi.org/10.1007/s11886-010-0101-1
  43. Lakomkin SV, Skvortsov AA, Goryunova TV, Masenko VP, Tereshchenko SN. Galectin-3 — a New Biomarker for Diagnostics and Outcome of Chronic Heart Failure. Kardiologiya. 2012;52:(3):67-72. (In Russ.)
  44. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of HF after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012;58:267-273. https://doi.org/10.1373/clinchem.2011.174359
  45. Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk ÂManag. 2010;6:691-699. https://doi.org/10.2147/vhrm.s5306
  46. Xue Y, Clopton P, Peacock W, et al. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated HF. Eur J Heart Fail. 2011;13:37-42. https://doi.org/10.1093/eurjhf/hfq210
  47. Miller WL, Hartman KA, Burritt MF, et al. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009;54:1715-1721. https://doi.org/10.1016/j.jacc.2009.07.025
  48. Friedl A, Stoesz SP, Buckley P, et al. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31:433-441. https://doi.org/10.1023/a:1003708808934
  49. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated HF. J Card Fail. 2010;16:49-54. https://doi.org/10.1016/j.cardfail.2009.07.003
  50. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the ÂOPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360:752-760. https://doi.org/10.1016/s0140-6736(02)09895-1
  51. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute HF: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated HF (GALLANT) trial. Eur J Heart Fail. 2011;13:846-851. https://doi.org/10.1093/eurjhf/hfr087
  52. Macfarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet. 1993;341:511-514. https://doi.org/10.1016/0140-6736(93)90275-l
  53. Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute HF) trial. Eur J Heart Fail. 2012;14:278-286. https://doi.org/10.1093/eurjhf/hfr177
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.